

The Threat of Multidrug Resistant Organisms (MDROs) in Hospitalized Patients

Tessa Andermann, MD MPH*
Immunocompromised Infectious Diseases
UNC-Chapel Hill

1

Disclosures

- None

2

Overview

- Antimicrobial resistance (AMR)
- Drivers of AMR
- Risk factors for infection with MDROs
- Superbugs and super-resistance
 - ESBL-E, CRE/CPE, CRAB, DTR
- Consequences/costs of AMR

3

The Threat of Antibiotic Resistance

- WHO: “antibiotic resistance one of the three greatest threats to human health”
- US: annual additional costs of infections caused by resistant organisms \$21-34 billion
- Impact on all aspects of modern medicine
 - Surgery
 - Oncology
 - Transplantation

4


Resistance is Global

Location	E. coli (%)	Klebsiella spp. (%)	Enterobacter spp. (%)
USA (2000)*	~2	~5	~3
UK (1999)	~3	~10	~10
Korea (1999)*	~30	~15	~15
China (2001)	~55	~25	~25
Taiwan (2002)	~20	~10	~10


Isturiz. Int J of Antimicrob Agents 2008;32:s201

5


Where did antimicrobial resistance originate from?




7




8




9




10




11



12




13




14




15



16




17



18


Risk Factors for Infections with Multidrug-Resistant Organisms (MDROs)

19



20

Trends in Resistant Enterobacteriaceae




Asensio et al. Eurosurveillance 2011;16:1

Vatopoulos. Eurosurveillance 2008;1:3:1

21

Risk Factors for Infections with Multidrug-Resistant Organisms (MDROs)



22


But first some definitions...

23

Focus of AMR Lecture: GNRs

- Two primary types of GNRs
 - Fermenters: Enterobacteriaceae/Enterobacterales* (gut-associated)
 - Non-fermenters: Environment-associated organisms (water, surfaces, etc)

24



25

Focus of AMR Lecture: GNRs

- Two primary types of GNRs
 - Fermenters: Enterobacteriaceae/Enterobacterales (gut-associated)
 - Non-fermenters: Environment-associated organisms (water, surfaces, etc)
- Two primary resistance types discussed today
 - Extended-spectrum beta-lactamases (ESBL)
 - Define by resistance to 3rd-generation cephalosporins
 - Carbapenem resistance
 - Carbapenem resistant Enterobacterales/Enterobacteriaceae (CRE)
 - Some produce carbapenemases (NDM, KPC)
 - Carbapenemase producing Enterobacterales (CPE)
 - Others result from the combination of multiple drug-resistance mechanisms

26

ESBL... What's in a Name?

Genotypic ESBL

- presence of ESBL gene
 - Whole genome sequencing
 - Targeted PCR

Phenotypic "ESBL"

- often a synonym for resistance to extended-spectrum cephalosporins (e.g. ceftriaxone)
- sometimes other phenotypic testing
- NOTE: remember AmpC enzymes
 - Chromosomal, inducible (e.g. *Enterobacter cloacae*) vs. plasmid-mediated (e.g. *E. coli*)

27

Family	Nomenclature	Characteristics
TEM	Temoneira, the patient infected with the first isolate expressing TEM-1	Point mutation variants of TEM-1 or TEM-2
SHV	Sulphydryl reagent variable	Point mutation variants of SHV-1
IRT	Inhibitor-resistant TEM	TEM variants that are resistant to inhibition by clavulanate and sulbactam, but do not have ESBL phenotype
CMT	Complex mutant derived from TEM-1	TEM variants that are resistant to inhibition by clavulanate and sulbactam and also have ESBL phenotype
CTX-M	Cefotaxime-hydrolysing β-lactamase isolated in Munich	Derived from the chromosomal β-lactamase from <i>Kluvera</i> spp. Preferentially hydrolyses cefotaxime
GES	Guano-extended spectrum	More prevalent in <i>P. aeruginosa</i> than Enterobacterales
PER	Pseudomonas extended resistant	More prevalent in <i>P. aeruginosa</i> and <i>A. baumannii</i> than Enterobacterales
VEB	Vietnam extended-spectrum β-lactamase	Inhibition by newer β-lactamase inhibitors is variable
BEL	Belgium extended β-lactamase	Preferentially hydrolyses ceftazidime and aztreonam compared with cefotaxime
TLA	Named after the Tzotzil Indians (Mexico), from whom the first isolate was obtained	Inhibition by newer β-lactamase inhibitors is variable
SFO	From <i>Serratia fonticola</i>	Preferentially hydrolyses ceftazidime and aztreonam compared with cefotaxime
OXY	From <i>Klebsiella oxytoca</i>	Inducible
		Chromosomally encoded

Castanheira et al. JAC-Antimicrobial Resistance 2021;3(3) <https://doi.org/10.1093/jacamrd/rvab001>

28

CDC-Defined CRE

US Centers for Disease Control and Prevention (CDC)

- 2012 CRE definition:
 - Non-susceptible to imipenem, meropenem, OR doripenem (MIC > 1 mcg/ml), AND
 - resistant to all 3rd gen. cephalosporins tested
- 2015 (current) CRE definition:
 - **Resistant** to imipenem, meropenem, doripenem (MIC ≥4 mcg/ml), AND/OR **ertapenem** (MIC ≥2 mcg/ml) AND/OR
 - Documented to produce carbapenemase

"CRE" ≠ Carbapenemase Production (CPE)


29

Carbapenemases


- KPC: Most common carbapenemase encountered in Enterobacterales in US
 - 13 variants; KPC-2 and KPC-3 most common
 - Class A serine-carbapenemase
 - Hydrolyzes carbapenems, cephalosporins, penicillins, aztreonam
- Other carbapenemases much less common in US
 - NDM, OXA, VIM, etc
 - Serine- and metallo-carbapenemases

Ke et al. Biochem 2007;46:5732

30



31



32

Risk factors & at-risk population

	Enterobacteriaceae	Non-fermenters
Risk factors	LOS ICU stay Catheters / devices Ventilation Prior antibiotics Travel	LOS ICU stay Catheters / devices Ventilation Prior antibiotics Trauma (esp. burns)
At-risk population	Acute settings Recent travel to areas of high prevalence Potential for community spread	High-risk patients Esp in ICU and burn units Rarely community-acquired infection.

ECDC CPE risk assessment, 2011.
Peleg et al. *Clin Microbiol Rev* 2008;21:538-582.


33

Risk factors are common across many MDR-pathogens


Risk Factors	Methicillin-Resistant <i>Staphylococcus aureus</i> (11, 12, 16-26)	Vancomycin-Resistant Enterococcus (27-48)	Extended-Spectrum β -Lactamase-Producing Gram-Negative Bacilli (49-57)	Clostridium difficile (58-77)
Advanced age	1.2 to 1.3 (17, 23)	2.6 (45)	NS (49, 51, 54, 56)	1.0 to 14.1 (60, 69, 74, 77)
Underlying disease				
Renal failure	† (12, 17, 18, 22, 23, 26)	4.4 to 6.98 (35, 42)	† (51), NS (49, 56, 57)	1.71 to 6.7 (66, 76)
Hematologic cancer	† (12, 17, 23, 26, 41, 42)	8.4 (33)		
Hepatic failure	† (12, 17, 23, 26)	2.3 to 6.1 (29, 30, 32, 47)	11.6 (53)	2.0 (63)
Severity of illness	1.9 (24)	4.1 to 2.9 (32, 45)	3.6 (52)	3.1 (66)
Interhospital transfer of a patient: patient from a nursing home	6.9 (24)			
Extended length of stay	1.7 to 17.5 (16-19, 21-23, 25, 26)	1.1 to 2.9 (28, 31-34, 38, 44)	1.1 to 9.0 (49, 50, 57)	1.3 to 3.6 (62, 67, 75)

Safdar & Maki. *Ann Intern Med* 2002;136:834


34




35




36



37




38




39




40




41




42



43




44




45




46



47



48



49

CRE in US (CRACKLE-2 data)




- Prospective, observational, multi-center, cohort study
- 2016-2017
- Consecutive hospitalized patients with CDC-defined CRE
- Analysis of first unique 1,040 patients from 49 US medical centers



van Duin et al. Lancet ID 2020; 20(6):731-741.

50



51


CDC-CRE: 3 subsets

All isolates met CDC criteria for CRE at local micro lab

- CPE:** Carbapenemase-producing Enterobacteriales
 - Carbapenemase gene present on whole genome sequencing and/or targeted PCR
- Non-CP-CRE:** Non-carbapenemase-producing CRE
 - No carbapenemase gene present
 - Carbapenem resistance confirmed in central laboratory
- U-CRE:** “Unconfirmed” CRE
 - No carbapenemase gene present
 - Carbapenem susceptible in central laboratory (resistant by local testing)


van Duin et al. Lancet ID 2020; 20(6):731-741.

52




53

Outcomes are Similar in All Three Patient Groups




* "Events" include lack of clinical response, unsuccessful discharge, and adverse events


54




55




56




57



58



59



60




61

Higher Mortality for All GNRs with Difficult-to-Treat Resistance

Difficult-to-Treat Resistance (DTR)

- Non-susceptibility to all first-line agents:
 - Piperacillin-tazobactam
 - Ceftazidime/Cefepime
 - Aztreonam
 - Meropenem/Imipenem-cilastatin
 - Ciprofloxacin/Levofloxacin



Kadri et al. Clin Infect Dis 2018;67(12):1803-1814

62

Summary

- MDROs are a growing threat to hospitalized patients
- Worse outcomes in patients with MDRO infections vs. susceptible organisms
- Carbapenem-resistant Gram-negative bacteria especially worrisome
 - Limited treatment options
 - Poor outcomes

63

Why did the dinosaur-killing-comet come to earth?

Why does the cat wake up one hour before he has to be fed?

*Why is the sky blue? What makes waterproof things waterproof?
Why does my brother always bother me?
How come we don't have wings and fly like birds?*

Questions?

*What kind of skulls do ant-eaters have?
What are we going to have for dinner?
Why do people cause pollution?*

What is coldness made out of?

*What is the smallest thing on earth?
What are electrons made of?
Why do people need to sleep?
How does electricity power technology?*

64